CMS Coverage Guidance: Reasonable/Necessary Not Defined, But Approached
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Medicare & Medicaid Services will release by year-end a draft guidance to aid regulators and manufacturers in determining levels of clinical evidence required for coverage decisions
You may also be interested in...
Prophylactic ICD Cost Considerations: Will They Upstage MCAC Data Review?
CMS' referral to the Medicare Coverage Advisory Committee of a national coverage determination for an expanded ICD indication raises the bar for the type of clinical evidence needed to secure reimbursement
Prophylactic ICD Cost Considerations: Will They Upstage MCAC Data Review?
CMS' referral to the Medicare Coverage Advisory Committee of a national coverage determination for an expanded ICD indication raises the bar for the type of clinical evidence needed to secure reimbursement
McClellan Outlines Vision For Device User Fees, Third-Party Inspections
Incoming FDA commissioner Mark McClellan, MD/PhD, is pledging to hold the agency to premarket review performance goals mandated under the "Medical Device User Fee and Modernization Act" if the bill becomes law